Psychological morbidity associated with ovarian cancer screening: results from more than 23 000 women in the randomised trial of ovarian cancer screening (UKCTOCS)

被引:38
|
作者
Barrett, J. [1 ]
Jenkins, V. [2 ]
Farewell, V. [3 ]
Menon, U. [4 ]
Jacobs, I. [5 ]
Kilkerr, J. [2 ]
Ryan, A. [4 ]
Langridge, C. [2 ]
Fallowfield, L. [2 ]
机构
[1] Univ Cambridge, Dept Publ Hlth & Primary Care, Cardiovasc Epidemiol Unit, Cambridge, England
[2] Univ Sussex, SHORE C, Brighton BN1 9RX, E Sussex, England
[3] Inst Publ Hlth, Med Res Council Biostat Unit, Cambridge, England
[4] UCL, EGA Inst Womens Hlth, London, England
[5] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Anxiety; ovarian cancer; population screening; programme; psychological morbidity; QUALITY-OF-LIFE; METAANALYSIS; ADHERENCE; RISK;
D O I
10.1111/1471-0528.12870
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To examine the psychological sequelae associated with abnormal screening in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Design Prospective, longitudinal randomised control trial. Setting Sixteen UKCTOCS centres. Sample Women aged 50-70 years randomised to annual multimodal screening, ultrasound screening or control groups. Methods Two groups were followed for 7 years: (1) a random sample (n = 1339), taken from all three study groups; and (2) an events sample (n = 22 035) of women with abnormal screens resulting in the need for repeat testing of either low or higher level intensity. Main outcome measures Patient-reported measures of anxiety (scores ranging from 20 to 80) and psychological morbidity. Results In the random sample the mean difference between anxiety scores after a repeat screening and those following an annual screening was 0.4 (95% CI -0.46, 1.27), and in the events sample it was 0.37 (95% CI 0.23, 0.51). The risk of psychological morbidity was only increased in the event sample for women requiring higher level repeat screening (OR 1.28; 95% CI 1.18, 1.39). The risk of psychological morbidity in women with ovarian cancer was higher at both 6 weeks (OR 16.2; 95% CI 9.19, 28.54) and 6 months (OR 3.32; 95% CI 1.91, 5.77) following surgery. Conclusions Screening does not appear to raise anxiety but psychological morbidity is elevated by more intense repeat testing following abnormal annual screens, and in women after surgical treatment for ovarian cancer.
引用
收藏
页码:1071 / 1079
页数:9
相关论文
共 50 条
  • [31] Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
    Partridge, Edward
    Kreimer, Aimee R.
    Greenlee, Robert T.
    Williams, Craig
    Xu, Jian-Lun
    Church, Timothy R.
    Kessel, Bruce
    Johnson, Christine C.
    Weissfeld, Joel L.
    Isaacs, Claudine
    Andriole, Gerald L.
    Ogden, Sheryl
    Ragard, Lawrence R.
    Buys, Saundra S.
    OBSTETRICS AND GYNECOLOGY, 2009, 113 (04): : 775 - 782
  • [32] Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    Dilley, James
    Gentry-Maharaj, Aleksandra
    Ryan, Andy
    Burnell, Matthew
    Manchanda, Ranjit
    Kalsi, Jatinderpal
    Singh, Naveena
    Woolas, Robert
    Sharma, Aarti
    Williamson, Karin
    Mould, Tim
    Fallowfield, Lesley
    Campbell, Stuart
    Skates, Steven J.
    McGuire, Alistair
    Parmar, Mahesh
    Jacobs, Ian
    Menon, Usha
    GYNECOLOGIC ONCOLOGY, 2023, 179 : 123 - 130
  • [33] Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    Dilley, James
    Burnell, Matthew
    Gentry-Maharaj, Aleksandra
    Ryan, Andy
    Neophytou, Christina
    Apostolidou, Sophia
    Karpinskyj, Chloe
    Kalsi, Jatinderpal
    Mould, Tim
    Woolas, Robert
    Singh, Naveena
    Widschwendter, Martin
    Fallowfield, Lesley
    Campbell, Stuart
    Skates, Steven J.
    McGuire, Alistair
    Parmar, Mahesh
    Jacobs, Ian
    Menon, Usha
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 316 - 322
  • [34] The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The prostate cancer screening results in context
    Berg, Christine D.
    ACTA ONCOLOGICA, 2011, 50 : 12 - 17
  • [35] Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOS): a randomised controlled trial (vol 387, pg 945, 2015)
    Jacobs, J. J.
    Menon, U.
    Ryan, A.
    LANCET, 2016, 387 (10022): : 944 - 944
  • [36] Screening for Ovarian Cancer in Asymptomatic Women
    Lu, Karen H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (06): : 557 - 558
  • [37] Screening of symptomatic women for ovarian cancer
    Tone, Alicia A.
    Huntsman, David G.
    Miller, Dianne M.
    LANCET ONCOLOGY, 2012, 13 (04): : E137 - E138
  • [38] Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors - Preliminary data from the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial
    Hartge, P
    Hayes, R
    Reding, D
    Sherman, ME
    Prorok, P
    Schiffman, M
    Buys, S
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (05) : 1232 - 1237
  • [39] Screening for ovarian cancer - We now need a definitive randomised trial
    Urban, N
    BRITISH MEDICAL JOURNAL, 1999, 319 (7221): : 1317 - 1318
  • [40] Ovarian cancer screening in women with a family history of breast or ovarian cancer
    Lacey, James V., Jr.
    Greene, Mark H.
    Buys, Saundra S.
    Reding, Douglas
    Riley, Thomas L.
    Berg, Christine D.
    Fagerstrom, Richard M.
    Hartge, Patricia
    OBSTETRICS AND GYNECOLOGY, 2006, 108 (05): : 1176 - 1184